Condensed Consolidated Statements Of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013
REVENUES:
Net pharmaceutical product sales	$ 430,960		$ 535,744
Devices revenues	123,767		122,652
Other revenues	39,882		98
TOTAL REVENUES	594,609		658,494
COSTS AND EXPENSES:
Cost of revenues	251,961		254,381
Selling, general and administrative	226,704		227,232
Research and development	41,680		38,769
Litigation-related and other contingencies	626,151		68,232
Asset impairment charges	0		1,100
Acquisition-related and integration items	45,269	[1]	558	[1]
OPERATING (LOSS) INCOME FROM CONTINUING OPERATIONS	(597,156)		68,222
INTEREST EXPENSE, NET	53,398		44,276
LOSS ON EXTINGUISHMENT OF DEBT	9,596		11,312
OTHER INCOME, NET	(6,032)		(18,269)
(LOSS) INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAX	(654,118)		30,903
INCOME TAX	(215,421)		9,250
(LOSS) INCOME FROM CONTINUING OPERATIONS	(438,697)		21,653
DISCONTINUED OPERATIONS, NET OF TAX (NOTE 3)	5,419		4,950
CONSOLIDATED NET (LOSS) INCOME	(433,278)		26,603
Less: Net income attributable to noncontrolling interests	3,634		11,254
NET (LOSS) INCOME ATTRIBUTABLE TO ENDO INTERNATIONAL PLC	$ (436,912)		$ 15,349
NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO ENDO INTERNATIONAL PLC ORDINARY SHAREHOLDERS—BASIC:
Continuing operations, basic (usd per share)	$ (3.42)		$ 0.19
Discontinued operations, basic (usd per share)	$ 0.01		$ (0.05)
Basic (usd per share)	$ (3.41)		$ 0.14
Continuing operations, diluted (usd per share)	$ (3.42)		$ 0.19
Discontinued operations, diluted (usd per share)	$ 0.01		$ (0.05)
Diluted (usd per share)	$ (3.41)		$ 0.14
WEIGHTED AVERAGE SHARES:
Basic (shares)	128,135		111,216
Diluted (shares)	128,135		113,189

[1] Acquisition-related and integration-items include costs directly associated with the closing of certain acquisitions, changes in the fair value of contingent consideration and the costs of integration activities related to both current and prior period acquisitions.